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Summary. Background: Matrix metalloproteinases (MMPs)
mediate tissue injury during stroke but also neurovascular
remodeling and we have shown that MMP-10 is involved
in atherothrombosis. Objective: The purpose of this study
was to examine the relationship between proMMP-10 and
clinical outcome, assessing inflammatory and proteolytic
markers, in patients with acute ischemic stroke. Methods:
We prospectively studied 76 patients with ischemic stroke
treated with tPA within the first 3 h from symptom onset,
compared with 202 non-tPA-treated ischemic stroke
patients and 83 asymptomatic subjects. Stroke severity
was assessed with the National Institutes of Health Stroke
Scale (NIHSS). Hemorrhagic transformation (HT) and
severe brain edema were diagnosed by cranial CT. Good
functional outcome was defined as a modified Rankin
scale score ≤ 2 at 90 days. Serum levels of MMP-9,
proMMP-10, TIMP-1, tumor necrosis factor-a (TNFa),
interleukin-6 and cellular fibronectin were measured at
admission. The effect of TNFa on endothelial proMMP-
10 was assessed in vitro. Results: Serum proMMP-10 con-
centration in ischemic stroke patients, non-treated or trea-
ted with t-PA, which was higher than age-matched
healthy subjects (P < 0.0001), was independently associ-
ated with higher infarct volume, severe brain edema, neu-
rological deterioration and poor functional outcome at
3 months (all P < 0.05), but not with HT. proMMP-10
levels were also independently and positively associated
with circulating levels of TNFa (P < 0.0001), which
induced its endothelial expression in vitro, both mRNA
and protein. MMP-9, however, was only associated with
HT and severe edema (all P < 0.05). Conclusions:
Increased serum proMMP-10 after acute ischemic stroke,
associated with TNFa, is a new marker of brain damage
and poor outcome.
Keywords: biological markers, inflammation, matrix me-
talloproteinases, stroke, tumor necrosis factor-alpha.
Introduction
Stroke is the third leading cause of death after cardiovas-
cular disease and cancer, and stroke survivors have an
increased chance of losing functional independence [1].
Thrombolytic therapy has been shown to be beneficial for
acute stroke, although conditioned by the limited time
window of treatment and the risk of hemorrhagic trans-
formation (HT) and other neurological complications [2].
Recently there has been an emphasis on the role of
matrix metalloproteinases (MMPs) in stroke. MMPs are
matrix-degrading enzymes with multifactorial actions
strictly regulated via modulation of gene expression, com-
partmentalization, activation and inhibition by specific
endogenous tissue inhibitors of metalloproteinases (TIM-
Ps) [3]. Most MMPs are expressed after external induction
by cytokines and growth factors in an inactive form, com-
prising a pro-domain upstream of the catalytic domain,
and activation proceeds through its removal, catalyzed by
furin-like convertases, by members of the plasminogen/
plasmin cascade or by other MMPs. MMPs are rapidly
up-regulated after cerebral ischemia, where they have been
implicated in brain injury, blood-brain barrier (BBB) leak-
age, HT and also cell death [4]. Dysregulation of neuro-
vascular MMPs during acute stroke has been proposed to
underlie tissue damage by degradation of the neurovascu-
lar matrix and disruption of cell-matrix homeostasis,
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explaining some complications of the thrombolytic therapy
[5]. However, MMPs also participate in beneficial neuro-
vascular remodeling during stroke recovery [6]. Among
them, MMP-9 has been proposed to play an important
role because it is increased in the plasma of acute ischemic
stroke patients, associated with lesion volume [7] and BBB
disruption [8], and its levels may predict intracranial hem-
orrhagic complications after thrombolysis [9,10]. Further-
more, MMP-9 KO mice display reduced infarct size [11]
and less BBB damage [12] after focal ischemia.
MMP-10, a member of the stromelysins family capable
of degrading various components of the extracellular
matrix and activating other MMPs, is secreted as zymo-
gen (proMMP-10) that eventually may be activated by
other proteases, such as plasmin [13]. Our group has
shown that vascular MMP-10 mRNA expression can be
induced by inflammatory stimuli [14,15], and that
increased serum proMMP-10 is associated with subclini-
cal atherosclerosis [16] and inflammatory conditions [17].
Besides, we have recently reported that active MMP-10
has a profibrinolytic effect in vivo [18]. In spite of avail-
able data suggesting that MMP-10 is involved in vascular
disease, inflammation and also fibrinolysis, a role for
MMP-10 has not been assessed in human ischemic stroke.
Our primary aim was to investigate whether serum proM-
MP-10 is associated with HT, brain edema and clinical
outcome in patients with acute ischemic stroke treated or
not with tPA. Secondly, we compared it with other estab-
lished inflammatory and proteolytic markers.
Methods
Baseline characteristics of the study population
We studied two different cohorts of patients with acute
ischemic stroke: the first group included patients treated
with intravenous tPA and the second included patients
who did not receive tPA treatment. They were separately
analyzed due to the potential effect of the interaction
between tPA treatment and proMMP-10 levels on clinical
outcome. Sample size was calculated using the statistical
EPIDAT software (http://www.sergas.es/MostrarConti-
dos_N3_T01.aspx?IdPaxina=62713), based on a 10%
prevalence of symptomatic HT according to previous
studies [19]. The minimum sample size calculated to
detect this effect was made accepting an alpha level of
5% and 80% power.
The first cohort consisted of 76 patients with a first-ever
acute ischemic stroke treated with intravenous tPA (0.9 mg/
kg1 for 1 h) within 3 h from symptom onset in the Univer-
sity Hospital of Santiago de Compostela. All patients were
prospectively evaluated by using cranial CT and neurologi-
cal and functional scales during a follow-up period of
90 days. Patients with prior disability (modified Rankin
score [mRS] > 1) and known infectious, inflammatory or
cancer diseases at the time of treatment were excluded.
The second cohort was selected from 283 consecutive
patients with a first-ever ischemic stroke admitted to the
same hospital within 12 h of symptom onset who were
previously independent in their daily living activities.
Patients with cancer (n = 5), chronic inflammatory
(n = 7), severe hepatic (n = 4), renal (n = 3), hematologi-
cal (n = 2) or infectious diseases in the 15 days prior to
inclusion (n = 7) were excluded. Thirty-eight patients who
received thrombolytic treatment, eight patients who did
not agree to participate in the study and seven patients
lost during the follow-up were also excluded; thus, a total
of 202 patients were finally included.
Healthy subjects from the Clınica Universidad de Nava-
rra, apparently free from overt vascular disease, were also
included as controls as described previously [16]. Briefly,
we identified a subgroup of 83 subjects with a similar age
and sex distribution, from a population of 414 subjects
without evidence of symptomatic cardiovascular disease
according to the following criteria: (i) no history of heart
disease, stroke or peripheral arterial disease; and (ii) nor-
mal electrocardiogram and chest X-ray. Other exclusion
criteria were: substantial alteration of renal function (glo-
merular filtration < 60 mL/min1), presence of chronic
inflammatory disease, and administration of anti-inflam-
matory medication or antithrombotic or hormone therapy
in the two previous weeks. Subjects with acute infection
based on clinical criteria were also excluded. Patients were
considered to be hypertensive if they had systolic blood
pressure > 139 mmHg and/or diastolic pressure
> 89 mmHg and/or were using antihypertensive drugs.
This research was carried out in accordance with the
Declaration of Helsinki of the World Medical Association
(2000) and approved by the Ethics Committee of the
Servizo Galego de Saude (ischemic stroke patients), and
the Clinica Universidad de Navarra (control subjects).
Informed consent was obtained from each patient or their
relatives after full explanation of the procedures.
Clinical variables
All patients were admitted to an acute stroke unit and
treated following the European Stroke Organization
guidelines [20]. Medical history recording potential vascu-
lar risk factors, blood and coagulation tests, 12-lead elec-
trocardiogram, chest X-ray and carotid ultrasonography
were performed at admission. Stroke subtype was classi-
fied according to the TOAST criteria [21], and stroke
severity was assessed by a certified neurologist using the
National Institute of Health Stroke Scale (NIHSS) on
admission (or before tPA treatment when applicable), at
24  6 h and 48  6 h. Early neurological deterioration
(END) was diagnosed in those patients whose NIHSS
score worsened by 4 points or more within the first 48 h.
Functional outcome was evaluated at 3 months using the
mRS; this scale classifies patients into seven categories: 0,
no symptoms at all; 1, no significant disability despite
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some symptoms, able to carry out all usual activities; 2,
slight disability, unable to carry out all previous activities,
but able to look after own affairs without assistance; 3,
moderate disability, requiring some help, but able to walk
without assistance; 4, moderately severe disability, unable
to walk and attend to own bodily needs without assis-
tance; 5, severe disability, bedridden, incontinent and
requiring constant nursing care and attention; 6, dead.
Good outcome was defined as mRS score ≤ 2 (indepen-
dent patients) and poor outcome as mRS score > 2
(dependent or dead patients).
Neuroimaging variables
CT scans were carried out at admission and between days
4 and 7. Patients who received tPA were studied before
infusion and 24–36 h after treatment. Early CT signs of
infarction were evaluated on admission, and infarct vol-
ume and HT were assessed on the follow-up CT. HT was
classified according to the European-Australasian Coop-
erative Acute Stroke Study (ECASS II) [22] and defined
as symptomatic when it was associated with END. Infarct
volume was calculated on the follow-up CT by using the
formula 0.5 9 a 9 b 9 c, where a and b are the largest
perpendicular diameters and c is the number of 1-cm
thick sections that contain the lesion. Severe brain edema
grouped patients with grade III (shift of midline struc-
tures) or malignant brain edema (midline shift and com-
pression of the basal cisterns associated with a rapid
deterioration of consciousness).
Outcome variables
In the two cohorts of ischemic stroke patients, the analysed
endpoints were infarct volume, symptomatic HT, severe brain
edema, END and poor functional outcome at 3 months.
Laboratory tests
Venous blood samples, drawn from all patients at admis-
sion (before tPA treatment when applicable) were col-
lected in Vacutainer tubes (Becton Dickinson, Madrid,
Spain), allowed to clot for 60 min, centrifuged at
3000 9 g for 10 min, and the serum was immediately ali-
quoted, frozen and stored at 80 °C until analysis. Serum
MMP-9, proMMP-10 and TIMP-1 were measured with
commercially available quantitative enzyme-linked immu-
nosorbent assay (ELISA) kits (R&D Systems, Abingdon,
UK) according to the manufacturer’s instructions with a
serum dilution of 1:100, 1:2 and 1:100, respectively. The
ELISA kit for proMMP-10 (DM1000, R&D Systems had
been formerly labeled as ‘total MMP-10’ and used for
total MMP-10 determination in previous publications by
our group [13–18,23,24]. Serum levels of IL-6 and TNFa
were measured by using an immunodiagnostic IMMU-
LITE 1000 System (Diagnostic Products Corporation, Los
Angeles, CA, USA) and cellular fibronectin (cFn) was mea-
sured by ELISA (Biohit Plc, Helsinki, Finland). Determina-
tions were performed by a trained technician blinded to
clinical and neuroimaging data. Inter- and intra-assay coef-
ficients of variation for ELISAs and immunodiagnostic
assays were < 8%.
Cell cultures
Human umbilical vein endothelial cells (HUVEC) were
isolated from human umbilical cords by digestion with
collagenase A (Invitrogen, Carlsbad, CA, USA) as
described [13], grown until confluency, subcultured and
used between passages 3 and 5. Cells were seeded in 24-
well plates and at confluence were arrested overnight and
stimulated with 1–5 ng/mL1 human recombinant TNFa
(Peprotech, Rocky Hill, NJ, USA).
Real-Time PCR
RNA was extracted from cells and reverse transcribed.
Real-time PCR was performed using commercially
available gene expression assays (PrimeTime qPCR
Assays, Integrated DNA Technologies, Leuven, Belgium)
for human MMP-10 (Hs.PT.49a.4393655.g) and human
glyceraldehyde-3-phosphate dehydrogenase (Hs.PT.39a.22
214836), which was used to normalize results.
MMP-10 protein secretion
Total MMP-10 concentration was measured in condi-
tioned media from TNFa-stimulated HUVEC with an
ELISA designed for the analysis of cell culture supernates
(DuoSet DY910, R&D systems). Inter- and intra-assay
coefficients of variation for the ELISA were < 6%.
The degree of MMP-10 activation in conditioned media
was estimated by western blot. Briefly, proteins were sep-
arated by denaturing polyacrylamide gel electrophoresis
(NuPAGE 4–12% Bis-Tris, Invitrogen, Carlsbad, CA,
USA) and electrotransferred onto nitrocellulose mem-
branes (iBlot, Invitrogen). Blots were incubated with a
monoclonal antibody directed to the catalytic domain of
MMP-10 (MAB9101, R&D Systems). Bound antibody
was detected using a goat anti-mouse horseradish peroxi-
dase-conjugated antibody (sc2005, Santa Cruz Biotechnol-
ogies, Santa Cruz, CA, USA) and a chemiluminescent
detection system (ECL Advance, GE Healthcare, Chal-
font St Giles, Buckinghamshire, UK).
Statistical analysis
The results were expressed as percentages for categorical
variables and as mean (SD) or median (interquartile
range) for the continuous variables depending on whether
their distribution was normal or not. Proportions
were compared using the chi-square or Fisher’s test, while
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continuous variables between groups were compared with
Student’s t or Mann–Whitney tests. Spearman’s or Pear-
son’s analyses were used for bivariate correlations. ANOVA
was used to analyze the relationship between stroke sub-
types and molecular marker levels. The influence of
molecular marker levels on END, HT, severe brain edema
and poor functional outcome (mRS > 2 at 3 months) was
assessed by logistic regression analysis, while the influence
on infarct volume was assessed by multivariable linear
regression models. Each logistic regression analysis or
multivariable linear regression model was adjusted for
those variables with a proven biological relevance for
each endpoint to avoid the possibility of finding some
spurious associations. Residual plots were examined to
detect potential non-linear relationships between the out-
come variable and continuous independent variables.
Results were expressed as adjusted odds ratios (ORs) or
Beta estimate with the corresponding 95% confidence
intervals (CIs). The statistical analysis was conducted
using SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Table 1 shows the characteristics of the study population.
We prospectively studied 76 acute ischemic stroke patients
treated with i.v. tPA (58% male, mean age
66.9  11.3 years). Mean time to treatment from symptom
onset was 140  31 min (also for blood sampling). Stroke
subtype was classified as atherothrombotic (20%), cardio-
embolic (54%), lacunar (3%) and undetermined (24%)
according to the TOAST criteria. Another group of 202
acute ischemic stroke patients who did not receive throm-
bolytic therapy was included in the study, with similar
baseline characteristics (54% men, mean age
73.5  11.3 years), but longer time from onset of symp-
toms to blood sampling (218  107 min) and different
stroke subtype profile (Table 1). Finally, a third group of
83 control subjects (62% men, mean age 64.8  9.5 years)
was also included.
Analysis of ischemic stroke patients treated with tPA
In comparison with the age-matched control population,
tPA-treated stroke patients showed much higher concen-
trations of proMMP-10 (P < 0.0001), which were not
associated with either stroke subtype or early (2 h after
tPA) or late (up to 24 h after tPA) recanalization. How-
ever, proMMP-10 was independently associated with
infarct volume (Beta estimate, 13.08; 95% CI, 7.58–
82.92), after adjusting for diastolic blood pressure, plate-
let count, proximal obstruction, basal NIHSS and early
CT signs. An independent association was also found for
MMP-9, cFn, IL-6 and TNFa (Table 2).
Patients with symptomatic hemorrhage (11%) exhibited
increased proMMP-10 and MMP-9 levels (P = 0.008 and
P < 0.0001, respectively), together with cFn (P < 0.0001)
and TNFa (P < 0.05, Table 3). However, cFn (per each
1 lg) was the only variable independently associated with
HT (OR, 1.09; 95% CI, 1.01–1.18), after adjusting for
hypodensity volume, END and history of peripheral arte-
riopathy.












Age, years (SD) 64.8 (9.5) 66.9 (11.3) 73.5 (11.3)





14 (17%) 15 (20%) 53 (26%)
High blood
pressure, n (%)
24 (29%) 42 (55%) 120 (59%)
Previous statin
treatment, n (%)
21 (25%) 18 (23%) 45 (22%)
Smoking, n (%) 15 (18%) 26 (34%) 28 (14%)
Previous CV
disease, n (%)
4 (5%) 12 (16%) 35 (17%)
Systolic blood
pressure, mmHg
133.7 (20.2) 148.7 (23.3) 153.2 (30.3)
Diastolic blood
pressure, mmHg
81.0 (9.4) 76.9 (16.2) 82.5 (17.4)
Glucose, mg/dL1 105.7 (29.7) 131.6 (43.3) 139.7 (65.1)
proMMP-10, pg/mL1 555.4 (179.1) 817.0 (525.0) 1069.5 (692.7)
Stroke diagnosis (TOAST criteria)
Atherothrombotic,
n (%)
– 15 (20%) 18 (9%)
Cardioembolic,
n (%)
– 41 (54%) 71 (35%)
Lacunar,
n (%)
– 2 (3%) 24 (12%)
Undetermined,
n (%)
– 18 (24%) 89 (42%)
Table 2 Multivariable linear regression analysis evaluating the rela-
tionship between some molecular markers and infarct volume







MMP-9 (ng/mL1) 5.52 (1.82, 9.21) 0.24 (0.01, 0.70)
proMMP-10 (pg/mL1) 15.33 (1.20, 18.66) 13.08 (7.58, 82.92)
TIMP-1 (ng/mL1) 0.38 (0.16, 0.92) 0.32 (0.36, 0.99)
Cellular fibronectin
(lg/mL1)
2.56 (1.00, 4.10) 2.04 (0.60, 3.47)
IL-6 (pg/mL1) 10.80 (8.87, 12.73) 9.86 (7.51, 12.20)
TNF-a (pg/mL1) 15.50 (8.25, 12.75) 8.99 (6.59, 11.40)
*Adjusted for diastolic blood pressure, platelet count, proximal
obstruction, basal NIHSS and early CT signs.
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On the other hand, as shown in Table 3, proMMP-10,
MMP-9 and cFn were significantly elevated in patients
with severe brain edema (13%). These molecular mark-
ers were also independently associated with severe brain
edema (all P < 0.01) after adjusting for age, NIHSS at
admission, maximal temperature within 24 h, early CT
signs of infarction and hypodensity volume (Table 4).
proMMP-10, MMP-9, IL-6, cFn and TNFa were
highly increased in patients with END (Table 3). How-
ever, only proMMP-10 remained independently associ-
ated in the logistic regression analysis (OR, 1.32; 95%
CI, 1.01–1.72), after adjusting for diastolic blood pres-
sure, symptomatic hemorrhage and hypodensity volume.
Likewise, proMMP-10 (1146.2  521.2 vs.
466.7  271.5 pg/mL1, P < 0.0001), IL-6 (16.2  8.2
vs. 5.8  4.1 pg/mL1, P < 0.0001), cFn (29.7  16.3
vs. 21.8  14.3 lg/mL1, P = 0.045) and TNFa
(19.4  7.3 vs. 9.2  4.2 pg/mL1, P < 0.0001) were sig-
nificantly higher in patients with poor functional out-
come (mRS > 2) at 3 months. Logistic regression
analysis showed that serum levels of proMMP-10 were
independently associated with poor outcome (OR, 1.61;
95% CI, 1.09–2.17) after adjusting for age, history of
atrial fibrillation, glucose levels, basal NIHSS, END,
hypodensity volume and early CT signs of infarction
(Table 5).
Finally, the relationship between proMMP-10 and
inflammatory markers was explored and a very strong
correlation was observed with TNFa (r = 0.941,
P < 0.0001; Fig. 1A), being the only independent associ-
ation found after multivariable linear regression analysis
(Beta estimate, 59.49; 95% CI, 51.90–67.09). In contrast,
MMP-9 was strongly correlated (r = 0.634, P < 0.0001;
Fig. 1B) and independently associated with cFn (Beta
estimate, 27.47; 95% CI, 19.34–35.61).
Analysis of ischemic stroke patients non-treated with tPA
proMMP-10 was also measured in a second group of
ischemic stroke patients that did not receive tPA, in
order to assess whether the proMMP-10 relationship
with brain edema, neurological deficit, infarct volume
and functional outcome was independent of the throm-





























































































































































































































































































































































































































































































































































































































































































Table 4 Crude and adjusted OR of severe brain edema for molecular





proMMP 10 (per 100 pg) 1.60 (1.18–3.02) 1.67 (1.22–3.12)
MMP 9 (per 100 ng) 1.41 (1.16–2.19) 1.41 (1.13–1.95)
cFn (per 1 lg) 1.10 (1.04–1.23) 1.13 (1.10–1.17)
*Adjusted for age, NIHSS at admission, early CT signs > 33% and
hypodensity volume.
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proMMP-10 levels than control subjects, as expected, but
also higher proMMP-10 levels than the tPA-treated group
(Table 1). proMMP-10 concentration was similar in
patients with different etiological stroke subtypes.
No differences in proMMP-10 levels could be observed
in those patients who had HT (9%), while it was
highly increased in the six patients (3%) with END
(1408.1  913.4 vs. 3424.1  744.9 pg/mL1, P < 0.0001).
However, proMMP-10 levels were not independently
associated with END (OR, 1.12; 95% CI, 0.92–3.07) after
adjusting for age, maximal temperature within the first
24 h, basal glucose levels, basal NIHSS, infarct volume
and early CT signs of infarction. In contrast, proMMP-
10 levels were significantly correlated with infarct size
Table 5 Crude and adjusted OR of poor functional outcome (mRS > 2 at 3 months) in ischemic stroke patients
tPA-treated Non tPA-treated
OR (95% CI), crude OR (95% CI), adjusted* OR (95% CI), crude OR (95% CI), adjusted*
proMMP-10 (per 100 pg) 2.03 (1.40–2.64) 1.61 (1.09–2.17) 4.02 (1.81–8.35) 3.83 (1.50–6.13)
TNF-a (per 1 pg) 1.35 (1.16–1.48) 1.21 (1.02–1.53)
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Fig. 1. MMPs are associated with inflammatory markers in tPA-treated acute ischemic stroke patients. (A) Correlation between proMMP-10
and TNFa. (B) Correlation between MMP-9 and cellular fibronectin. (C) Time course of endothelial MMP-10 mRNA expression (mean  SD,
n = 4) after stimulation with TNFa. (D) TNFa induces proMMP-10 protein release in human umbilical vein endothelial cell (HUVEC)-condi-
tioned medium (mean  SD, n = 4). (E) Representative western blot showing 52 kDa band corresponding to proMMP-10 in conditioned med-
ium from TNFa-treated HUVEC. *, P < 0.05; †, P < 0.01.
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(r = 0.693; P < 0.0001) and this association was main-
tained in the multivariable linear regression analysis (Beta
estimate, 3.82; 95% CI, 1.63–5.13) after adjusting for gen-
der, history of atrial fibrillation, maximal temperature
within 24 h, basal glucose levels, platelets, fibrinogen, leu-
kocytes, basal NIHSS and TOAST criteria.
On the other hand, proMMP-10 increased with the
severity of brain edema (Figure S1) and was significantly
elevated (2268.6  1052.3 vs. 866.1  353.7 pg/mL1,
P < 0.0001) in patients with severe edema (13%), as was
its inhibitor TIMP-1 (477.0  266.1 vs. 358.3  165.3 ng/
mL1, P = 0.008). proMMP-10 levels (per 100 pg) were
independently associated with severe brain edema (OR,
1.92; 95% CI, 1.56–3.12) after adjusting for age, maximal
temperature within 24 h, glucose levels, basal NIHSS,
infarct volume, early CT signs of infarction and TIMP-1
levels. No other difference or significant association could
be observed for TIMP-1 and any of the clinical parameters
analyzed, independently of the thrombolytic treatment.
Finally, proMMP-10 was also increased in patients with
poor functional outcome at 3 months (2410.1  605.9 vs.
769.4  366.5, P < 0.0001). The higher the proMMP-10
levels, the greater the severity of mRS (Figure S2). Logistic
regression analysis showed that proMMP-10 was indepen-
dently associated with poor outcome (OR, 3.83; 95% CI,
1.50–6.13) (Table 5).
Relationship between TNFa and endothelial MMP-10
The tight association observed between circulating TNFa
and proMMP-10 in patients subjected to thrombolysis led
us to study the effect of TNFa on MMP-10 expression in
human endothelial cells. As shown in Fig. 1(C), treatment
of HUVEC with TNFa induced a significant time and
dose-dependent increase in MMP-10 mRNA and protein.
mRNA induction was already patent at 4 h, peaked at
12 h and remained at high levels for up to 24 h. mRNA
up-regulation was accompanied by an increase in proM-
MP-10 secreted into the medium, starting at 2.2 h and
reaching statistical significance by 8 h (P < 0.05, Fig. 1D).
Conditioned medium was subjected to western blot in
order to corroborate MMP-10 up-regulation. The distinc-
tive 52 kDa band corresponding to proMMP-10 was pat-
ent 12 h after TNFa stimulation (Fig. 1E); this was more
noticeable at 24 h and even more intense with the higher
dose of TNFa, while it was barely detectable in non-trea-
ted HUVEC. The 43 kDa band corresponding to the
active MMP-10 could not be observed in any of the
experimental conditions tested.
Discussion
We show herein that proMMP-10 levels at admission are
significantly increased in ischemic stroke patients, irre-
spective of stroke subtype, and independently associated
with infarct volume, severe edema, poor outcome and cir-
culating TNFa, but not with hemorrhagic transformation.
We have also demonstrated that TNFa induces proM-
MP-10 expression in endothelial cells, suggesting that the
vascular wall can be a source of augmented proMMP-10.
Increased MMP expression after cerebral ischemia is
well documented, both experimentally and clinically, and
associated with brain tissue damage and hemorrhagic
transformation (reviewed in [25]). As most of the avail-
able evidence focused on MMP-2 and -9, the overall data
indicate that gelatinases play a deleterious role in the
acute setting by promoting BBB degradation. In particu-
lar, increased MMP-9 concentration after stroke has been
associated in humans with infarct volume, stroke severity,
hemorrhagic transformation and functional outcome
(reviewed in [26]). Moreover, it has been shown that
MMP inhibition reduces brain damage in experimental
models of stroke [27]. With this background, it was not
surprising that proMMP-10 was significantly increased in
patients with acute ischemic stroke subjected to thrombol-
ysis, although gelatinases and stromelysins have different
substrate specificity. This observation was in agreement
with a previous proteomic protease profiling [28] and a
report showing that MMP-10 was up-regulated in human
brain neurons after stroke [29]. We confirmed this result
in a second group of non-thrombolysed ischemic stroke
patients, in whom the proMMP-10 concentration was
even higher. As blood sampling was performed before
treatment, differences in proMMP-10 concentration
between the two cohorts could be due to their distinct
characteristics, even though no differences were found
among stroke subtypes, but also to the longer time from
acute stroke to blood sampling in patients who did not
receive tPA.
In our cohort of stroke patients receiving thrombolysis,
proMMP-10 was independently associated mainly with
variables related to brain damage (infarct volume, severe
edema, neurological deterioration and clinical outcome)
and inflammation (TNFa). In contrast, MMP-9 was more
associated with HT and cerebral edema, and also with
markers of vascular damage and BBB rupture (cFn), in
agreement with what had been previously reported for
this MMP [26,30]. Independent association of proMMP-
10 with infarct volume and clinical outcome in the second
group of patients further supports its role as a marker of
cerebral damage, while association with neurological dete-
rioration could not be confirmed, probably due to its low
incidence in this cohort (<3%).
These results and the lack of association between circu-
lating proMMP-10 and reperfusion could seem to be in
apparent conflict with a recent report from our group
demonstrating that thrombolysis with active MMP-10 is
as efficient as tPA in a preclinical model of ischemic
stroke, in terms of reperfusion time and infarct size, with
reduced hemorrhage risk [18]. However, there is no real
contradiction because active MMP-10 is required for effi-
cient thrombolysis and increased proMMP-10 does not
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imply necessarily more active MMP-10, as we have shown
in vitro with TNFa stimulation.
Vascular alterations in the acute phase of stroke result in
the disruption of BBB permeability, causing extravasation
of albumin and other high-molecular-weight compounds,
which leads to edema and increased intracranial pressure.
We have found that proMMP-10 is independently associ-
ated with severe edema formation, together with MMP-9
and cFn, in agreement with a previous report associating
these last two markers with malignant brain edema in clini-
cal studies [31]. However, we cannot claim a causal role for
proMMP-10, because we have shown previously that
proMMP-10 (up to 550 ng/mL1) does not induce endo-
thelial cytotoxicity [18] and we lack experimental evidence
linking proMMP-10 with endothelial activation and/or
damage, favouring vasoconstriction and increased perme-
ability of the BBB, which have been related to edema for-
mation and mortality after ischemia [32].
The first cells responding to brain ischemia are glial
cells, with transcription of early pro-inflammatory cyto-
kines, such as TNFa, which may contribute to both neu-
rotoxicity and neuroprotection either locally or by leaving
the damaged tissue and entering the circulation [33]. The
tight association between TNFa and proMMP-10 in
peripheral blood leads us to propose that TNFa released
by ischemic tissue could induce MMP-10 mRNA expres-
sion as part of the elicited response in the vascular wall.
Our in vitro results, demonstrating that TNFa induces
proMMP-10 production by endothelial cells, support this
hypothesis and are in agreement with previous results
from our group showing that endothelial MMP-
10 mRNA expression can be up-regulated by inflamma-
tory stimuli, such as C reactive protein,[14] thrombin [13]
and CD40 ligand [15], which also belongs to the TNFa
cytokine family. They are also in accordance with
increased proMMP-10 levels observed in human sepsis, a
systemic inflammatory condition [17]. Overall, MMP-10
up-regulation may be part of a vascular wall response to
an inflammatory stimulus (TNFa) triggered by the acute
ischemic event.
Limitations
We acknowledge that our research work has several limi-
tations that should be properly addressed in future stud-
ies, mainly the limited sample size. Also, in order to have
a complete scope, other MMPs should be studied, partic-
ularly those belonging to the same family (MMP-3 and
-11), together with their specific inhibitors, analyzing their
relationship with stroke severity and clinical outcome. We
provide solid evidence associating proMMP-10 with neu-
rological deterioration, severe edema and poor functional
outcome, but cannot prove a causal role for proMMP-10
in brain damage. Further studies are warranted in order
to examine proMMP-10 activation in acute stroke and
elucidate whether active MMP-10 could be mechanisti-
cally involved in neuronal damage.
Conclusion
The present study shows that increased proMMP-10 con-
centration after acute ischemic stroke is independently asso-
ciated with TNFa, brain damage, development of severe
cerebral edema and poor functional outcome, and thus may
represent a new marker for this disease irrespective of the
thrombolytic treatment and stroke etiology. Early risk
assessment in this leading cause of cardiovascular death
may allow for better and earlier intervention and improved
therapeutic strategies to effectively treat these patients.
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